FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020148377> ?p ?o ?g. }

• W2020148377 endingPage "460" @default.
• W2020148377 startingPage "453" @default.
• W2020148377 abstract "New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients with atrial fibrillation (AF). A systematic review and meta-analysis of randomized controlled trials was performed to compare the efficacy and safety of new oral anticoagulants to those of warfarin in patients with AF. The published research was systematically searched for randomized controlled trials of >1 year in duration that compared new oral anticoagulants to warfarin in patients with AF. Random-effects models were used to pool efficacy and safety data across randomized controlled trials. Three studies, including 44,563 patients, were identified. Patients randomized to new oral anticoagulants had a decreased risk for all-cause stroke and systemic embolism (relative risk [RR] 0.78, 95% confidence interval [CI] 0.67 to 0.92), ischemic and unidentified stroke (RR 0.87, 95% CI 0.77 to 0.99), hemorrhagic stroke (RR 0.45, 95% CI 0.31 to 0.68), all-cause mortality (RR 0.88, 95% CI 0.82 to 0.95), and vascular mortality (RR 0.87, 95% CI 0.77 to 0.98). Randomization to a new oral anticoagulant was associated with a lower risk for intracranial bleeding (RR 0.49, 95% CI 0.36 to 0.66). Data regarding the risks for major bleeding (RR 0.88, 95% CI 0.71 to 1.09) and gastrointestinal bleeding (RR 1.25, 95% CI 0.91 to 1.72) were inconclusive. In conclusion, the new oral anticoagulants are more efficacious than warfarin for the prevention of stroke and systemic embolism in patients with AF. With a decreased risk for intracranial bleeding, they appear to have a favorable safety profile, making them promising alternatives to warfarin. New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients with atrial fibrillation (AF). A systematic review and meta-analysis of randomized controlled trials was performed to compare the efficacy and safety of new oral anticoagulants to those of warfarin in patients with AF. The published research was systematically searched for randomized controlled trials of >1 year in duration that compared new oral anticoagulants to warfarin in patients with AF. Random-effects models were used to pool efficacy and safety data across randomized controlled trials. Three studies, including 44,563 patients, were identified. Patients randomized to new oral anticoagulants had a decreased risk for all-cause stroke and systemic embolism (relative risk [RR] 0.78, 95% confidence interval [CI] 0.67 to 0.92), ischemic and unidentified stroke (RR 0.87, 95% CI 0.77 to 0.99), hemorrhagic stroke (RR 0.45, 95% CI 0.31 to 0.68), all-cause mortality (RR 0.88, 95% CI 0.82 to 0.95), and vascular mortality (RR 0.87, 95% CI 0.77 to 0.98). Randomization to a new oral anticoagulant was associated with a lower risk for intracranial bleeding (RR 0.49, 95% CI 0.36 to 0.66). Data regarding the risks for major bleeding (RR 0.88, 95% CI 0.71 to 1.09) and gastrointestinal bleeding (RR 1.25, 95% CI 0.91 to 1.72) were inconclusive. In conclusion, the new oral anticoagulants are more efficacious than warfarin for the prevention of stroke and systemic embolism in patients with AF. With a decreased risk for intracranial bleeding, they appear to have a favorable safety profile, making them promising alternatives to warfarin." @default.
• W2020148377 created "2016-06-24" @default.
• W2020148377 creator A5010857889 @default.
• W2020148377 creator A5027894587 @default.
• W2020148377 creator A5042964192 @default.
• W2020148377 creator A5058591639 @default.
• W2020148377 creator A5072116483 @default.
• W2020148377 date "2012-08-01" @default.
• W2020148377 modified "2023-10-01" @default.
• W2020148377 title "Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation" @default.
• W2020148377 cites W1965320794 @default.
• W2020148377 cites W1982179895 @default.
• W2020148377 cites W1983727955 @default.
• W2020148377 cites W1997637512 @default.
• W2020148377 cites W2015398317 @default.
• W2020148377 cites W2062786076 @default.
• W2020148377 cites W2068476516 @default.
• W2020148377 cites W2071869524 @default.
• W2020148377 cites W2074119210 @default.
• W2020148377 cites W2083035480 @default.
• W2020148377 cites W2090225839 @default.
• W2020148377 cites W2097624562 @default.
• W2020148377 cites W2097854437 @default.
• W2020148377 cites W2106981695 @default.
• W2020148377 cites W2115787552 @default.
• W2020148377 cites W2118092611 @default.
• W2020148377 cites W2127441164 @default.
• W2020148377 cites W2136489990 @default.
• W2020148377 cites W2151983329 @default.
• W2020148377 cites W2156402206 @default.
• W2020148377 cites W2162508946 @default.
• W2020148377 cites W2170189969 @default.
• W2020148377 cites W2313548138 @default.
• W2020148377 cites W3022903699 @default.
• W2020148377 doi "https://doi.org/10.1016/j.amjcard.2012.03.049" @default.
• W2020148377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22537354" @default.
• W2020148377 hasPublicationYear "2012" @default.
• W2020148377 type Work @default.
• W2020148377 sameAs 2020148377 @default.
• W2020148377 citedByCount "393" @default.
• W2020148377 countsByYear W20201483772012 @default.
• W2020148377 countsByYear W20201483772013 @default.
• W2020148377 countsByYear W20201483772014 @default.
• W2020148377 countsByYear W20201483772015 @default.
• W2020148377 countsByYear W20201483772016 @default.
• W2020148377 countsByYear W20201483772017 @default.
• W2020148377 countsByYear W20201483772018 @default.
• W2020148377 countsByYear W20201483772019 @default.
• W2020148377 countsByYear W20201483772020 @default.
• W2020148377 countsByYear W20201483772021 @default.
• W2020148377 countsByYear W20201483772022 @default.
• W2020148377 countsByYear W20201483772023 @default.
• W2020148377 crossrefType "journal-article" @default.
• W2020148377 hasAuthorship W2020148377A5010857889 @default.
• W2020148377 hasAuthorship W2020148377A5027894587 @default.
• W2020148377 hasAuthorship W2020148377A5042964192 @default.
• W2020148377 hasAuthorship W2020148377A5058591639 @default.
• W2020148377 hasAuthorship W2020148377A5072116483 @default.
• W2020148377 hasConcept C126322002 @default.
• W2020148377 hasConcept C127413603 @default.
• W2020148377 hasConcept C164705383 @default.
• W2020148377 hasConcept C168563851 @default.
• W2020148377 hasConcept C204243189 @default.
• W2020148377 hasConcept C2776301958 @default.
• W2020148377 hasConcept C2778661090 @default.
• W2020148377 hasConcept C2778810321 @default.
• W2020148377 hasConcept C2779161974 @default.
• W2020148377 hasConcept C2780290652 @default.
• W2020148377 hasConcept C2780638905 @default.
• W2020148377 hasConcept C2780645631 @default.
• W2020148377 hasConcept C42219234 @default.
• W2020148377 hasConcept C44249647 @default.
• W2020148377 hasConcept C71924100 @default.
• W2020148377 hasConcept C78519656 @default.
• W2020148377 hasConcept C82789193 @default.
• W2020148377 hasConceptScore W2020148377C126322002 @default.
• W2020148377 hasConceptScore W2020148377C127413603 @default.
• W2020148377 hasConceptScore W2020148377C164705383 @default.
• W2020148377 hasConceptScore W2020148377C168563851 @default.
• W2020148377 hasConceptScore W2020148377C204243189 @default.
• W2020148377 hasConceptScore W2020148377C2776301958 @default.
• W2020148377 hasConceptScore W2020148377C2778661090 @default.
• W2020148377 hasConceptScore W2020148377C2778810321 @default.
• W2020148377 hasConceptScore W2020148377C2779161974 @default.
• W2020148377 hasConceptScore W2020148377C2780290652 @default.
• W2020148377 hasConceptScore W2020148377C2780638905 @default.
• W2020148377 hasConceptScore W2020148377C2780645631 @default.
• W2020148377 hasConceptScore W2020148377C42219234 @default.
• W2020148377 hasConceptScore W2020148377C44249647 @default.
• W2020148377 hasConceptScore W2020148377C71924100 @default.
• W2020148377 hasConceptScore W2020148377C78519656 @default.
• W2020148377 hasConceptScore W2020148377C82789193 @default.
• W2020148377 hasIssue "3" @default.
• W2020148377 hasLocation W20201483771 @default.
• W2020148377 hasLocation W20201483772 @default.
• W2020148377 hasOpenAccess W2020148377 @default.
• W2020148377 hasPrimaryLocation W20201483771 @default.
• W2020148377 hasRelatedWork W1679435851 @default.

• next